Deutsche Bank reissued their neutral rating on shares of Roche (VTX:ROG) in a research report sent to investors on Monday.
Several other research analysts have also recently issued reports on ROG. Barclays set a CHF 305 target price on Roche and gave the company a buy rating in a research report on Thursday, December 21st. Nord/LB reaffirmed a buy rating on shares of Roche in a research report on Wednesday, December 27th. JPMorgan Chase set a CHF 300 target price on Roche and gave the company a buy rating in a research report on Friday, December 29th. Jefferies Group set a CHF 300 target price on Roche and gave the company a buy rating in a research report on Friday, January 5th. Finally, UBS set a CHF 260 target price on Roche and gave the company a neutral rating in a research report on Monday, January 8th. Five research analysts have rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of CHF 253.30.
Shares of VTX:ROG opened at CHF 219.60 on Monday. Roche has a 12-month low of CHF 214.30 and a 12-month high of CHF 273.
COPYRIGHT VIOLATION WARNING: “Roche (ROG) Earns Neutral Rating from Deutsche Bank” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/04/17/roche-rog-earns-neutral-rating-from-deutsche-bank.html.
Rogers Corporation designs, develops, manufactures, and sells engineered materials and components worldwide. The company's Advanced Connectivity Solutions segment offers circuit materials and solutions for connectivity applications in wireless communications infrastructure, automotive, connected devices, wired infrastructure, consumer electronics, and aerospace/defense.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.